Acid Phosphatase Total and prostatic fraction Serum

Cancer

Report in 48Hrs

At Home

No Fasting Required

Details

Enzyme test, includes prostatic acid phosphatase fraction.

₹666₹951

30% OFF

Acid Phosphatase Total and Prostatic Fraction Serum - Comprehensive Guide

Why is it done?
- Test measures the level of acid phosphatase enzyme in serum, specifically distinguishing between total acid phosphatase and prostatic acid phosphatase (PAP) fraction
- Primarily indicated for detection and monitoring of prostate cancer, particularly advanced or metastatic disease
- Evaluation of patients with elevated PSA (prostate-specific antigen) levels to assess prostate pathology
- Investigation of bone pain or suspected bone metastases in cancer patients, as acid phosphatase may indicate osteoclast activity
- Diagnosis of benign prostatic hyperplasia (BPH) or prostatitis when elevated in serum
- Monitoring response to prostate cancer treatment and assessing disease progression or recurrence
- Typically performed during initial prostate cancer workup, prior to treatment initiation, and periodically during surveillance
Normal Range
- Total Acid Phosphatase: 0.0-5.0 ng/mL (or 0.0-5.0 IU/L depending on laboratory) for adult males
- Prostatic Acid Phosphatase (PAP) Fraction: 0.0-3.0 ng/mL or <1% of total acid phosphatase
- Unit of Measurement: nanograms per milliliter (ng/mL) or International Units per liter (IU/L); reference ranges vary by laboratory method
- Normal Results: Indicate no significant prostate disease or malignancy; normal acid phosphatase metabolism with prostatic enzyme within expected limits
- Elevated Results: May indicate prostate cancer (especially metastatic), BPH, prostatitis, or trauma to prostate tissue
- Borderline Values: Between 1.5-3.0 ng/mL may warrant repeat testing or correlation with other clinical findings and PSA levels
- Note: Laboratory reference ranges should always be consulted as different assay methods may have different cutoff values
Interpretation
- Mildly Elevated (1.5-5.0 ng/mL): May suggest benign prostatic conditions such as BPH, recent ejaculation, prostate trauma, or inflammation; does not necessarily indicate cancer
- Moderately Elevated (5.0-10.0 ng/mL): Warrants further investigation; may indicate localized prostate cancer or significant prostatic disease; correlation with PSA and clinical findings essential
- Significantly Elevated (>10.0 ng/mL): Suggestive of advanced prostate cancer with possible bone metastases or significant prostatic malignancy; indicates need for immediate further investigation and treatment planning
- Prostatic Fraction Elevation: If PAP fraction represents >50% of total acid phosphatase, strongly suggests prostate origin of elevated enzyme; more specific for prostate pathology than total acid phosphatase alone
- Factors Affecting Results: Recent prostate examination, digital rectal exam (DRE), ejaculation within 24-48 hours, prostate biopsy, urinary catheterization, vigorous exercise, or prostate manipulation can temporarily elevate levels; medications like acid-lowering agents may affect results
- Clinical Significance - Prostate Cancer: Elevated PAP is more specific for prostate cancer than total acid phosphatase; useful in stratifying cancer risk but has lower sensitivity than PSA; combined with PSA provides better prognostic information
- Limited Modern Use: This test is less commonly ordered than in the past due to PSA's superior sensitivity and specificity; however, it remains valuable in specific clinical scenarios and when PSA results are inconclusive
- Post-Treatment Monitoring: Rising PAP levels after prostate cancer treatment may indicate recurrence or progression; declining levels suggest effective treatment response
Associated Organs
- Primary Organ: Prostate gland (male reproductive organ); acid phosphatase is abundantly produced by prostatic epithelial cells
- Secondary Sources: Osteoclasts in bone (elevated in bone metastases), platelets, red blood cells, and various other tissues; non-prostatic sources can elevate total acid phosphatase but not PAP fraction
- Associated Conditions - Prostate Cancer: Elevated PAP strongly associated with adenocarcinoma of prostate; particularly high in metastatic disease with bone involvement; indicates aggressive tumor behavior and poor prognosis
- Associated Conditions - Benign Prostatic Hyperplasia: Mild to moderate elevation may occur; generally less pronounced than in cancer; usually PAP fraction remains relatively low
- Associated Conditions - Prostatitis: Acute or chronic inflammation of prostate can cause elevation due to cellular damage and enzyme release; elevated levels typically resolve with treatment of infection
- Associated Conditions - Bone Metastases: Can elevate both total and prostatic acid phosphatase; indicates cancer has spread to skeletal system; associated with significant pain, fracture risk, and treatment complications
- Complications of Abnormal Results: Advanced prostate cancer may cause urinary obstruction, erectile dysfunction, pain, metastatic spread with systemic complications; bone metastases increase fracture risk and pathologic complications
Follow-up Tests
- Prostate-Specific Antigen (PSA): Primary screening test for prostate disease; more sensitive and specific than acid phosphatase; should be performed concurrently or immediately after abnormal acid phosphatase results
- Digital Rectal Examination (DRE): Clinical assessment of prostate size, texture, and nodularity; essential component of prostate cancer evaluation when acid phosphatase is elevated
- Transrectal Ultrasound (TRUS): Imaging of prostate gland to detect suspicious lesions; typically performed if elevated acid phosphatase and PSA warrant further investigation
- Prostate Biopsy: Definitive test to diagnose prostate cancer when imaging and PSA suggest malignancy; performed when combination of elevated acid phosphatase and PSA raises significant suspicion
- Bone Scan or PET Imaging: To detect bone metastases when significantly elevated acid phosphatase suggests advanced disease; helpful in staging and treatment planning
- Repeat Acid Phosphatase Testing: If initial result borderline or after patient avoidance of prostate-stimulating activities (24-48 hour waiting period); may help confirm findings and rule out false elevations
- Alkaline Phosphatase and Other Bone Markers: Assess bone involvement and osteoclast activity; elevated with bone metastases; useful in monitoring bone health in advanced cancer patients
- Monitoring Frequency for Prostate Cancer: During active treatment: every 1-3 months; post-treatment surveillance: every 3-6 months initially, then annually; at any sign of recurrence: more frequent testing warranted
- Comprehensive Metabolic Panel (CMP): To assess overall organ function and detect any metabolic abnormalities related to advanced malignancy; baseline before treatment initiation
Fasting Required?
- Fasting: No - fasting is NOT required for acid phosphatase testing
- Avoid Prostate Stimulation (48-72 hours before test): No ejaculation or sexual activity, no vigorous cycling or activities placing pressure on perineal area, no heavy weight-lifting or strenuous exercise
- Avoid Recent Prostate Procedures: No digital rectal examination, prostate biopsy, cystoscopy, or urinary catheterization within 48-72 hours of testing; minimum 5-7 days after biopsy recommended
- Medications: No specific medications need to be avoided; continue all regularly prescribed medications unless otherwise directed by healthcare provider; certain medications (fluoroquinolones) used for prostatitis may affect results
- Hydration: Normal fluid intake recommended; well-hydration may help with blood draw but is not critical
- Specimen Collection: Blood draw via venipuncture into appropriate collection tube; serum sample preferred; testing done at clinical laboratory; no special storage required if processed promptly
- Timing Considerations: Morning blood draw preferred as some diurnal variation may occur; consistent timing beneficial for serial monitoring; coordination with urologist or oncologist important for optimal clinical correlation
- Patient Information: Inform laboratory and physician of all recent prostate-related procedures, recent ejaculation, or activities that may elevate results; provides context for result interpretation

How our test process works!